1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,111 | 0,131 | 13:05 | |
| 0,115 | 0,126 | 11.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SINOMAB BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| Mo | SINOMAB BIO-B (03681): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 7 SEPTEMBER 2026 | 1 | HKEx | ||
| 31.08. | SINOMAB BIO-B (03681): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 | 1 | HKEx | ||
| 21.08. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 21.08. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 21.08. | SINOMAB BIO-B (03681): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD AT ROOM 3, 14/F, FAIRMONT HOUSE, 8 COTTON TREE DRIVE, CENTRAL, HONG ... | 1 | HKEx | ||
| 21.08. | SINOMAB BIO-B (03681): NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 21.08. | SINOMAB BIO-B (03681): (1) MAJOR TRANSACTION - DISPOSAL OF SUZHOU PROPERTY AND FACILITY; AND (2) NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 19.08. | SINOMAB BIO-B (03681): DATE OF BOARD MEETING | 1 | HKEx | ||
| 18.08. | SINOMAB BIO-B (03681): BOOK CLOSURE PERIOD FOR THE EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 18.08. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 18.08. | SINOMAB BIO-B (03681): RESIGNATION OF EXECUTIVE DIRECTOR | 2 | HKEx | ||
| 10.08. | SINOMAB BIO-B (03681): FURTHER DELAY IN DESPATCH OF CIRCULAR FOR MAJOR TRANSACTION | 1 | HKEx | ||
| 27.07. | SINOMAB BIO-B (03681): DELAY IN DESPATCH OF CIRCULAR FOR MAJOR TRANSACTION | 1 | HKEx | ||
| 24.07. | SINOMAB BIO-B (03681): GRANT OF SHARE OPTIONS | 4 | HKEx | ||
| 06.07. | SINOMAB BIO-B (03681): MAJOR TRANSACTION DISPOSAL OF SUZHOU PROPERTY AND FACILITY | 3 | HKEx | ||
| 03.07. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 03.07. | SINOMAB BIO-B (03681): APPOINTMENT OF EXECUTIVE DIRECTOR | - | HKEx | ||
| 12.06. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 12.06. | SINOMAB BIO-B (03681): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 12 JUNE 2026 AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR | 5 | HKEx | ||
| 14.05. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT PRESENTATION OF PRECLINICAL STUDIES OF ANTI-CGC ANTIBODY (HC2) AT SID ANNUAL MEETING 2026 | 5 | HKEx |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 17,550 | 0,00 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| TANGO THERAPEUTICS | 23,780 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,870 | 0,00 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| VERA THERAPEUTICS | 35,090 | +0,11 % | Vera Therapeutics: Erfolgreicher Start für Nierenmedikament TRUTAKNA | ||
| QIAGEN | 36,525 | -0,25 % | BERENBERG stuft QIAGEN NV auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Qiagen mit einem Kursziel von 40 Euro auf "Hold" belassen. Der Medizintechnik- und Life-Science-Sektor bleibe fundamental attraktiv, wie die... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,230 | +0,11 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 44,450 | +0,11 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 79,31 | 0,00 % | Jefferies erhöht Kursziel für Tarsus Pharmaceuticals nach Prognoseanhebung | ||
| ARCUTIS BIOTHERAPEUTICS | 23,880 | -0,02 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,410 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ERASCA | 15,890 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| ARCUS BIOSCIENCES | 24,570 | 0,00 % | Arcus Biosciences: Casdatifan-Strategie auf der Cantor Global Healthcare Conference im Fokus | ||
| IMMUNOVANT | 37,330 | -0,08 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,545 | 0,00 % | Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors | Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness NEEDHAM, Mass., Sept. 10, 2026... ► Artikel lesen | |
| MODERNA | 124,98 | +0,68 % | Moderna-Aktie bei 144 US$: Nächstes Hoch in Sicht? | Die Moderna-Aktie konnte gestern um +5,38% zulegen, nachdem der Kurs zuvor rund -34% korrigiert hatte. Damit zeigt sich nach dem deutlichen Rücksetzer eine erste Gegenbewegung. Nun stellt sich die entscheidende... ► Artikel lesen |
Das Unternehmen SINOMAB BIOSCIENCE LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,115 Euro und damit +1,77 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SINOMAB BIOSCIENCE LTD finden Sie auf Wallstreet Online.